Moffitt Cancer Center's impact on cancer research spans basic science, prevention and clinical research with a focus on translating discoveries into better care. These are some examples of the current research being conducted at Moffitt.
- Dmitry I. Gabrilovich, M.D., Ph.D., is leading pioneering work in myeloid-derived suppressor cells in sustaining tumor growth. His groundbreaking work in adaptive immunity has uncovered unique cellular mechanisms that in collaboration with others at Moffitt have led to the development of innovative immunotherapies.
- Alan F. List, M.D., Moffitt's CEO, and colleagues first demonstrated activity of lenalidomide in patients with low-risk myelodysplastic syndrome (MDS). Subsequent studies demonstrated further effectiveness, including combination therapies. These discoveries have changed the treatment and greatly improved outcomes for patients with MDS.
- Anna R. Giuliano, Ph.D., and colleagues contributed significantly to the research that led to the approval of the first HPV vaccine, Gardasil, for women. Building upon that work, she has led the way in providing definitive evidence that the HPV vaccine prevents various cancers in men, including genital, anal and oral cancers.
- Jeffrey S. Weber, M.D., Ph.D., and others at Moffitt contributed significantly to the approval and testing of the melanoma drug Vemurafenib, including important laboratory work in developing an inhibitor to overcome resistance to the drug that has led to improved outcomes.